Ligand Pharmaceuticals (LGND) Competitors

ADMA Biologics (NASDAQ:ADMA) and Ligand Pharmaceuticals (NASDAQ:LGND) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

Which has better earnings and valuation, ADMA or LGND?

ADMA Biologics has higher revenue and earnings than Ligand Pharmaceuticals. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$426.45M	10.24	$197.67M	$0.85	21.52
Ligand Pharmaceuticals	$167.13M	13.20	-$4.03M	-$7.12	-16.07

Which has more volatility and risk, ADMA or LGND?

ADMA Biologics has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.

Is ADMA or LGND more profitable?

ADMA Biologics has a net margin of 45.01% compared to Ligand Pharmaceuticals' net margin of -73.07%. ADMA Biologics' return on equity of 47.16% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	45.01%	47.16%	30.51%
Ligand Pharmaceuticals	-73.07%	-7.83%	-6.92%

Do institutionals and insiders hold more shares of ADMA or LGND?

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 3.5% of ADMA Biologics shares are owned by insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Does the media refer more to ADMA or LGND?

In the previous week, ADMA Biologics had 3 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 10 mentions for ADMA Biologics and 7 mentions for Ligand Pharmaceuticals. ADMA Biologics' average media sentiment score of 1.08 beat Ligand Pharmaceuticals' score of 0.81 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer ADMA or LGND?

ADMA Biologics currently has a consensus target price of $27.67, suggesting a potential upside of 51.23%. Ligand Pharmaceuticals has a consensus target price of $146.14, suggesting a potential upside of 27.76%. Given ADMA Biologics' stronger consensus rating and higher probable upside, equities analysts clearly believe ADMA Biologics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

ADMA Biologics beats Ligand Pharmaceuticals on 12 of the 17 factors compared between the two stocks.